ALSUntangled #72: Insulin.

Amyotrophic lateral sclerosis (ALS) insulin metabolism off-label treatment

Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
28 Nov 2023
Historique:
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: aheadofprint

Résumé

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.

Identifiants

DOI: 10.1080/21678421.2023.2288110 PMID: 38018119
pubmed: 38018119
doi: 10.1080/21678421.2023.2288110
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-4

Auteurs

Andrew Brown (A)

Department of Neurology, University of Miami, Miami, FL, USA.

Carmel Armon (C)

Department of Neurology, Loma Linda University Health, Loma Linda, CA, USA.

Paul Barkhaus (P)

Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.

Morgan Beauchamp (M)

UNC Health, UNC, Chapel Hill, NC, USA.

Tulio Bertorini (T)

Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.

Mark Bromberg (M)

Department of Neurology, University of Utah, Salt Lake City, UT, USA.

Javier Mascias Cadavid (JM)

ALS Department, Hospital Carlos III-La Paz, Madrid, Spain.

Gregory T Carter (GT)

Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.

Jesse Crayle (J)

Department of Neurology, St. Louis, MO, USA.

Eva L Feldman (EL)

Department of Neurology, University of Michigan, Ann Arbor, MI, USA.

Terry Heiman-Patterson (T)

Department of Neurology, Temple Health, Philadelphia, PA, USA.

Sartaj Jhooty (S)

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Alexandra Linares (A)

Medical School, Duke University, Durham, NC, USA.

Xiaoyan Li (X)

Department of Neurology, Duke University, Durham, NC, USA.

Elise Mallon (E)

Undergraduate, Duke University, Durham, NC, USA.

Christopher Mcdermott (C)

Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK.
ORCID: 0000-0002-1269-9053

Tasnim Mushannen (T)

Department of Neurology, Duke University, Durham, NC, USA.

George Nathaniel (G)

Undergraduate, Duke University, Durham, NC, USA.

Gary Pattee (G)

Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.

Kaitlyn Pierce (K)

Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA.

Ari Rappoport (A)

Hebrew University of Jerusalem, Jerusalem, Isreal.

Dylan Ratner (D)

Undergraduate, Tulane University, New Orleans, LA, USA.

Lenka Slactova (L)

Institute of Biology and Medical Genetics, Charles University, Prague, Czech Republic, and.

Paul Wicks (P)

Independent Consultant, Lichfield, England, UK.
ORCID: 0000-0002-2293-9284

Richard Bedlack (R)

Department of Neurology, Duke University, Durham, NC, USA.

Classifications MeSH